Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
MDGL Weekly Chart

Old Forum Content for MDGL

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: @mhuie $ETNB - Nice move off the bottom as it is rapidly moving to test that gap from the drop on 10/10. My sense is that many in the obesity space - and related Diabetes/liver/NASH & cardio spaces - are moving on good industry-wide obesity data ...
  • woodman: $TERN is next up (Q3) in the NASH therapeutic area (TA) - for its Phase 2a top line data for TERN-501 (THR-B Agonist) alone and in combo with TERN-101 (FXR Agonist) (DUET trial). Other bios focusing on NASH ($AKRO $MDGL $ETNB $VKTX) have moved well post-NASH-data reporting.
  • woodman: @BarryC $NVO - it has cut production due to demand. This is a HUGE market. There will be some pie for a lot of players, even up and comers that are still a few years away. LLY probably holds the crown right now, or will as soon as Mounjaro is approved for obesity. Oral administration will be an important advancement in the space. Up and comers include $MDGL $VKTX $TERN and others. GIP as part of the agonist regime seems to be key.
  • woodman: @woodman $NVO $MDGL $VKTX $TERN https://www.cnbc.com/2023/05/04/novo-nordisk-cuts-some-supply-of-wegovy-drug-amid-soaring-demand.html#:~:text=Novo%20Nordisk%20said%20Thursday%20it,patients%20in%20the%20U.S.%20market.
  • BarryC: @woodman $NVO $MDGL $VKTX $TERN Ty, yes, I was familiar that they had to cut production due to demand. The rest of is WAY over my paygrade, lol... On a different note $NOV is "kinda" a decent set up which is MOST important to me. I will add those symbols and watch more closely, ty for filling me in :-)
  • woodman: $MDGL breaking out from high consolidation after the huge gap up in December. This will be the first of the NASH stocks to be approved - targeting approval by EOY. I think it will lift other boats in the harbor.
  • woodman: @woodman $MDGL - $VKTX, on the timeline, is behind MDGL, but it has other assets - most notably, its obesity drug (still in early stages) which, also is differentiated within the obesity therapeutic area given its oral administration (I believe working on both oral and injectable). It also has a drug for X-ALD - adrenomyeloneuropathy (AMN). Plus, folks are hopeful that the coming data for NASH will show better outcomes. We should be getting Phase 2b data for NASH this month. But both are doing well.
  • woodman: $VKTX - Others in this the NASH family that I own include $TERN and $ETBN. I should have bought $MDGL too, but I don't have it. That said, all of these will move on good news for MDGL which is furthest along out of this group (currently seeking FDA approval) and believed to be a BO target.
  • woodman: $TERN pullback and holding (with a bounce today) the prior resistance (12.41)/now support area. This will move higher if coming data for $VKTX is good and/or more good news for $MDGL comes out. It has data (NASH/obesity) coming in Q3.
  • woodman: $TERN itching to move out of high consolidation. Seems to be getting pulled by the momentum of others in the NASH therapeutic area (TA). See $VKTX $MDGL and perhaps $ETNB.
  • roddog101: @woodman $TERN $VKTX $MDGL $ETNB how long can these keep running? we talking co that dont even have drug to market yet, man they are red hot tho
  • woodman: @roddog101 $TERN $VKTX $MDGL $ETNB - Big Pharma has taken quite an interest in and buying companies with Phase 2 assets in big markets. I think that, in part, is putting wind in VKTX's sails (along with very early Obesity data and other stuff in their pipeline). If the Phase 2b data for its NASH candidate are good, there will be even more speculation that it's an acquisition target.
  • woodman: $TERN $VKTX $MDGL $ETNB - $MRK just bought Prometheus (immunology) before Phase 3 has started. I think there was another recent acquisition of a company with a Phase 2 drug.
  • woodman: $TERN $VKTX $MDGL $ETNB - Bellus was just bought by $GSK which has results through Phase 2, and now is in Phase 3 with no results due this year.
  • roddog101: @woodman $TERN $VKTX $MDGL $ETNB any idea when $VKTX data is coming out? best case worse case scenario?
  • woodman: $TERN $VKTX $MDGL $ETNB - I think it's shortsighted to view VKTX as simply NASH, or even simply as NASH and obesity. They have a lot in the pipeline. An acquiring company would be getting a number of potential assets - 6 programs, 3 or which are in phase 2.
  • woodman: @roddog101 $TERN $VKTX $MDGL $ETNB Coming this Q. I don't know the date. Expected to do well, and it's configuration - GLP-1 and GIP agonist) is expected to significantly lessen the side effects found in others' drug candidates (i.e. nausea and vomiting). There's a high level of excitement.
  • woodman: $MDGL furthest along in the NASH race, breaking out today.
  • roddog101: @woodman $MDGL Man that whole space is hyped up and seems overbought imo, time will tell tho
  • woodman: @roddog101 $MDGL - Making me $$, so I won't complain.
  • woodman: $TERN another NASH stock I'm in is trying to break out. Others I'm in are $VKTX and $ETNB (I'm not in $MDGL but I should be. It's the furthest along among the NASH stocks and is expected to file NDA for accelerated approval this half of the year).
  • woodman: $VKTX @Steve71 - I chased and bought this today. Small because it's so extended. But up it goes again. Getting a bounce in other NASH stocks too. $ETNB (long) $MDGL (np).
  • marklesparkle: @woodman $VKTX $ETNB $MDGL $AKRO is another NASH which I just got shaken out of today for small profit even as I'm saying theres nothing wrong with it. But not afraid to jump back in on a PB now
  • woodman: $VKTX - @steve71, have you looked into this biotech? Very interesting, especially with $MDGL's recent P3 success on its NASH drug. VKTX's NASH candidate, though only in Phase 2b, could be even better than MDGL's. VKTX flew higher in sympathy on the MDGL news. VKTX has other drug candidates in the pipeline as well. https://vikingtherapeutics.com/pipeline/overview/ I think VKTX can go much higher, though I'd like to see a pullback after such a jump higher. It has multiple catalysts 1H2023. ($MDGL, btw, may be a buyout candidate now.) $ETNB is another in the NAHS area (I'm still holding this one from the 7s and 8s, though did sell a little in the 10s). NP currently in MDGL or VKTX though I intend to start a position in VKTX at some point and keeping an eye on both.
  • steve71: @woodman $VKTX $MDGL $VKTX Yes, I have been aware for a while and a 5% tracking position. It got away from me. Like you, I am waiting for a pullback. : (
  • woodman: @steve71 $VKTX $MDGL - Thanks.
  • traderdl: $MDGL - new high - day 4
  • woodman: @traderdl $MDGL - Keeps going. $VKTX in sympathy. $ETNB, which I'm still in, is taking a little breather, but showing life again as I type (also in sympathy).
  • woodman: Current #biotech and Big #Pharma that I'm in: $ARDX (gift drop 2 days ago; catalyst with news likely in January - see my prior posts) $CPRX (keeps going) $ORMP (strong today; catalyst into January for P3 results for oral insulin; also, CEO just talke ...
  • traderdl: @fiebs $AKRO $MDGL news
  • traderdl: $VKTX sympathy play with $MDGL
  • woodman: $ETNB - One I recently mentioned. Well, it got thwacked this morning on good news from $MDGL. I had a small position in ETNB, which I doubled up on with the morning's thwacking. It still has a place in the therapeutic area, I think. It's up about 14% from the bottom of this morning's big move down.
  • bRobert: $MDGL . Spec with base/set up in place High upside with trigger $165/$195 . Alert >$145 . Short squeeze potential . 26%.
  • bRobert: $MDGL Working Nice base $180+
  • bRobert: $MDGL Spec setting up for big move $180+ Partial position and patient. will add on confirmation on pb/b
  • bRobert: $MDGL Nice base . Long this spec .Size does matter. Prevents shake outs in volatile issues High targets Shorts 26% 7d
  • bRobert: $MDGL short squeeze. Phase 3 $180 target
  • bRobert: $MDGL . Another SPEC I'm holding . 25% . short 11+ . d Phase 3 breakout. This has room to run. Position size key.
  • bRobert: @scottrades $IRBT #ShortSqueeze $CLF $PYX $HEAR $CGC $OSTK $GH $AMRS $PLSE $MDGL Here are a few more with claustrophobic shorts.
  • bRobert: Participating in a number of short squeezes or possibilities of . $PYX $HEAR $CGC $OSTK $GH $AMRS $PLSE $MDGL A record for me Watching for follow through.
  • bRobert: $MDGL interesting possibility in motion 25% Short 11+ days
  • bRobert: $GH $MDGL still climbing
  • woodman: For what little it may be worth: GS #Biotech stocks where GS analysts see the highest M&A probability: $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT
  • shoredriver: @woodman $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT #Biotech .....$CLVS.....ugly memory.......
  • woodman: @shoredriver $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT #Biotech - BMRN has been on that list forever. Broken clock. Eventually they will be right about it getting bought.
  • gwenzee: @woodman $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT #Biotech I've been waiting for someone to scoop up INCY for quite awhile. At least it has come off of the recent lows. Someone is throwing me a lifeline which I really need on this one.
Visit the Trading Forum to join in the discussion.
Stock Price $212.04
Change -4.60%
Volume 625,065

Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).

Request Video of MDGL
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!